Research reveals that δ-receptor agonists like KNT-127 alleviate IBS symptoms by modulating gut-brain interactions and ...

Naloxone is a fantastic tool in reducing opioid deaths, but gentler versions would be helpful for fighting overdose ...

As the body of research expands on the potential of glucagon-like peptide-1 receptor agonists to address various health ...

The Food and Drug Administration announced the approval of a new non-opioid pain medication this week, marking the first time ...

Meet suzetrigine, a non-opioid that promises to avoid addiction risk. But some experts say it can't replace opioids ...

A new opioid-free pain medication was approved by the FDA on Thursday, marking a non-addictive alternative for patients.

Federal officials approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated with opioid​ medications like Vicodin and OxyContin.

The Phase IIa results continue a surge of momentum in a treatment space that last week saw the approval of Vertex’s Journavx ...

The US Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or overdose linked to drugs like Vicodin and OxyContin.

Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.